1. Secord E; Milla CE; Shah B. Picture of the month: Ecthyma Gangrenosum secondary to Pseudomonas aeruginosa. Am J Dis Children 1993, 147:795-796.
2. Milla CE; Wielinski C; Warwick WJ. High-strength pancreatic enzymes. Lancet, 1994; 343 : 599.
3. Milla CE; Wielinski,C.; Regelmann, WE. Clinical significance of the recovery of Aspergillus species from the respiratory secretions of cystic fibrosis patients. Pediatr Pulmonol 1996; 21:6-10.
4. Milla CE, Doherty L, Raatz S, Schwarzenberg SJ, Regelmann WE, Moran AM. The glycemic response to varying carbohydrate:fat ratios of dietary supplements in cystic fibrosis. J Parent Ent Nutr 1996; 20:182-186.
5. Shreve MR, Johnson SJ, Milla CE, Wielinski CL, Regelmann WE. Ribotyping and endonuclease subtyping in the epidemiology of Burkholderia cepacia. Am J Resp Crit Care Med 1997; 155:984-989.
6. Regelmann AG, Haseman JR, Elliott GR, Milla CE, Gray BH, Regelmann WE. Elastin degrading activity in cystic fibrosis bronchoalveolar lavage fluid is partly inhibited by secretory leukoprotease inhibitor and is related to lung structure and nutrition. (In review for publication in Pediatric Pulmonology).
7. Milla CE, Warwick WJ. Risk of death in cystic fibrosis patients with severely compromised lung function. (Submitted for publication to Chest).
1. Milla CE; Regelmann WE; Wielinski C. The distribution of the DF508 mutation in a group of deceased Cystic Fibrosis patients. Am Rev Respir Dis 1993; 147(4): A579.
2. Milla CE; Regelmann WE; Wielinski C. Comparison of the decline in pulmonary function in deceased cystic fibrosis patients homozygous for the DF508 mutation versus compound heterozygotes for the DF508 mutation. Am Rev Respir Dis 1993; 147(4): A464.
3. Milla CE; Wielinski C; Warwick WJ. Distal intestinal obstruction syndrome (DIOS) and association with pancreatic enzyme supplementation in a cohort of cystic fibrosis patients. Pharmacoepidemiology 1994; 3(S1):S30. (Also presented as a poster at the 10th International Conference on Pharmacoepidemiology, Stockholm, Sweden, 1994).
4. Wielinski C; Milla CE; Warwick WJ. Management effect due to the introduction of high potency pancreatic enzyme capsules (greater than 22,000 lipase units/capsule) for treatment of pancreatic insufficiency in cystic fibrosis. Pharmacoepidemiology 1994; 3(S1):S30. (Also presented as a poster at the 10th International Conference on Pharmacoepidemiology, Stockholm, Sweden, 1994).
5. Milla CE; Wielinski C, Warwick WJ. Survival analysis of a group of Cystic Fibrosis patients with FEV1 below 30% of predicted. Am J Resp Crit Care Med 1994, 149:676.
6. Milla CE; Wielinski C, Regelmann WE. Clinical significance of Aspergillus sp. in CF respiratory secretions. Pediatric Pulmonol 1994; S10: 257.
7. Milla CE; Wielinski C, Zirbes JM, Warwick WJ. Clinical characteristics of cystic fibrosis (CF) patients waiting for lung transplantation. Pediatric Pulmonol 1994; S10: 270.
8. Warwick WJ, Milla CE; Wielinski C. Epidemiologic investigation of the incidence of gastrointestinal problems in a cohort of CF patients and its relation to the use of high strength pancreatic supplements. Pediatric Pulmonol 1995; 19:85-86.
9. Milla CE, Regelmann WE. Development of a new method to study intraphagocytic bacterial killing. Pediatric Research 1995, 37(p2):184A.
10. Milla CE, Wielinski CL, Warwick WJ. Potential usefulness of cyclosporine as an antiinflammatory drug in cystic fibrosis patients with advanced lung disease. Am Journal Resp Crit Care Med 1995, 151 (pt 2 of 2): A249.
11. Shreve MR, Johnson S, Milla C, Wielinski C, Regelmann WE. Polymerase chain reaction based ribotyping and endonuclease subtyping are useful in determining Burkholderia cepacia transmission and blood stream invasion in cystic fibrosis patients. Am Journal Resp Crit Care Med 1995, 151 (pt 2 of 2): A740.
12. Milla CE, Doherty L, Raatz S, Schwartzenberg SJ, Regelmann WE, Moran A. Glycemic and respiratory responses to enteral formulas containing varying amounts of fat and carbohydrate in a group of cystic fibrosis patients with severe pulmonary function impairment. Pediatric Pulmonol 1995; S12:261.
13. Milla CE, Wielinski CL, Jacobs D, Warwick WJ. Rate of decline in FEV1 as a prognostic indicator among cystic fibrosis patients with different degrees of lung function impairment. Am Journal Resp Crit Care Med 1996, 153 (pt 2 of 2): A71.
14. Shreve MR, Johnson S, Milla CE, Wielinski C, Regelmann WE. Ribotyping and endonuclease subtyping in the epidemiology of Burkholderia cepacia Am Journal Resp Crit Care Med 1996, 153 (pt 2 of 2): A706.
15. Milla CE, Hite SH, Warwick WJ. Lung volume measurements in infants and young children with cystic fibrosis by a radiographic method. Am Journal Resp Crit Care Med 1997, 155 (pt 2 of 2): A646.
16. Shreve MR, Milla CE, Johnson AJ, Regelmann WE. Suitability of techniques of P. aeruginosa DNA fingerprinting to determine risk of acquisition in cystic fibrosis. Pediatric Research 1997, 41(p2):A
1. Milla CE, Regelmann WE. Use of bioluminescence as a marker of bacterial survival during phagocytosis and killing assays.
2. Milla CE, Wielinski CL, Zirbes JM, Warwick WJ. Clinical characteristics and course of cystic fibrosis patients waiting for lung transplantation: The University of Minnesota experience.
3. Milla CE, Jacobs DR, Warwick WJ. Rate of decline in FEV1 as a prognostic indicator among cystic fibrosis patients with different degrees of lung function impairment.
4. Cornfield DN, Barbato J, Maynard RC, Guiang S, DeRegnier RA, Milla CE, Rozenberg A. Effects of low dose, inhalational nitric oxide in persistent pulmonary hypertension of the newborn: Results of a randomized, controlled trial.
1. "Comparison of the decline in pulmonary function in deceased cystic fibrosis patients homozygous for the DF508 mutation versus compound heterozygotes for the DF508 mutation". Presented at the mini-symposium 'Cystic fibrosis: clinical studies', 1993 American Thoracic Society international conference, San Francisco, California, May 1993.
2. "Case presentation: Interaction of AIDS with cystic fibrosis in a 41 year old patient homozygous for DF508". Presented at the 'Fellows, clinical session', 7th North American Cystic Fibrosis Conference, Dallas, Texas, October 1993. (One of the seven presentations selected from a worldwide contest sponsored by the Cystic Fibrosis Foundation)
3. "A preventive medicine approach to asthma". Presented at the 4th Latin-American Pediatric Pulmonology Congress, Porlamar, Venezuela, September 1994.
4. "Cystic fibrosis: diagnostic tools and therapeutic management". Presented at the 4th Latin-American Pediatric Pulmonology Congress, Porlamar, Venezuela, September 1994.
5. "Development of a new method to study intraphagocytic bacterial killing". Presented at the Infectious Disease Session, 1995 Society for Pediatric Research meeting, San Diego, California, May 1995.
6. "Potential usefulness of cyclosporine as an antiinflammatory drug in cystic fibrosis patients with advanced lung disease". Presented at the discussion session 'Airway Inflammation in Cystic Fibrosis', 1995 American Thoracic Society international conference, Seattle, Washington, May 1995.
7. "Glycemic and respiratory responses to enteral formulas containing varying amounts of fat and carbohydrate in a group of cystic fibrosis patients with severe pulmonary function impairment". Presented at the workshop 'Latest Nutrition Research', 9th North American Cystic Fibrosis Conference, Dallas, Texas, October 1995.
8. "Nutrition in the acutely ill cystic fibrosis patient with CO2 retention". Presented at the workshop 'Gastrointestinal and metabolic complications in cystic fibrosis', 9th North American Cystic Fibrosis Conference, Dallas, Texas, October 1995.
9. "Longitudinal studies in cystic fibrosis". Department of
Pediatrics Grand Rounds, University of Minnesota, November 8 1995.